CVS Health posted one of its better days in recent memory on Tuesday, driven by a Medicare Advantage policy update that sent managed-care names broadly higher.
The Centers for Medicare & Medicaid Services finalized its 2027 Medicare Advantage and Part D payment rules, projecting a net average increase of 2.48% — translating to more than $13 billion in additional funding across the sector for calendar year 2027.
For CVS, that’s not a minor footnote. Through its Aetna unit, the company carries real exposure to Medicare Advantage, alongside its pharmacy benefit manager and retail pharmacy operations.
The market read the headline number as a positive. CVS stock climbed as much as 5.20% in Tuesday morning trading.
The update wasn’t entirely straightforward. CMS confirmed it will stick with the 2024 risk-adjustment model for 2027, and will exclude diagnoses from unlinked chart reviews in most risk-score calculations.
That’s a tighter standard that could affect insurers who leaned on coding-driven reimbursement strategies. For CVS, which runs a diversified operation, traders appeared to focus more on the funding increase than the risk-adjustment fine print.
The Stars ratings picture has also been improving for CVS. Its bonus-eligible Stars scores dropped sharply from 85% in 2022 to 21% in 2023 — a period that weighed heavily on Medicare Advantage margins.
Cantor Fitzgerald, which reiterated an Overweight rating with a $95 price target on Monday, said the Medicare Advantage unit still has further to go to reach 3% margins, but estimated that 2026 individual Medicare Advantage margins are slightly profitable.
The stock was trading at $73.28 before Tuesday’s move, a level Cantor and others view as undervalued relative to fair value.
The analyst community has largely maintained a constructive stance on CVS. The stock carries a consensus Buy rating with an average price target of $92.79.
Recent moves include Bernstein upgrading to Outperform with a $94 target in March, Piper Sandler holding Overweight while trimming its target to $99, and Argus Research maintaining a Buy at $90.
Leerink Partners also holds an Outperform with a $98 target, a view shaped in part by the recent FTC consent agreement involving Caremark and Zinc, which the firm saw as removing a layer of regulatory uncertainty.
On the corporate side, CVS recently announced an asset purchase agreement with GenieRx Holdings, positioning GenieRx as the stalking horse bidder in Omnicare’s court-supervised sale process.
The company also appointed John E. Gallina, formerly CFO at Elevance Health, to its board of directors and audit committee.
Next up: CVS reports Q1 2026 earnings on May 6. The Street is looking for EPS of $2.23 and revenue of $94.86 billion.
The post CVS Health (CVS) Stock Jumps 5% After CMS Locks In $13B Medicare Advantage Boost appeared first on CoinCentral.
